Business Context and Reporting Period
This Form 6-K filing by Novartis AG, dated December 7, 2006, reports on clinical data published in the New England Journal of Medicine regarding Glivec (imatinib). The filing focuses on the five-year results of the International Randomized Interferon versus STI571 (IRIS) study for patients with chronic myeloid leukemia (CML). While the filing includes historical 2005 financial data for context, it does not report specific financial results for the period ending December 7, 2006.
Key Financial Metrics
The filing does not provide current revenue, profit, cash flow, margins, debt, or liquidity figures for the reporting period. Historical data from 2005 is provided in the "About Novartis" section:
- 2005 Net Sales: USD 32.2 billion
- 2005 Net Income: USD 6.1 billion
- 2005 R&D Investment: Approximately USD 4.8 billion
Material Changes and Clinical Results
The primary material update concerns the long-term efficacy and safety of Glivec based on the IRIS study (1,106 patients across 16 countries):
- Overall Survival: Estimated at 95% at 60 months when excluding deaths unrelated to CML or prior transplantation. Overall survival considering all causes was 89% (range 86% to 92%).
- Disease Progression: The yearly risk of progression to advanced disease declined to 0.6% in the fifth year.
- Cytogenetic Response: Major cytogenetic responses increased from 85% to 92%; complete cytogenetic responses rose from 69% to 87% over five years.
- Approval Expansions: Glivec received EU approvals for myelodysplastic syndromes/myeloproliferative diseases (MDS/MPD), hypereosinophilic syndrome/chronic eosinophilic leukemia (HES/CEL), and Ph+ acute lymphoblastic leukemia (Ph+ ALL). It is now approved for six diseases in the EU and seven in the US.
Outlook, Risks, and Management Commentary
Management, represented by David Epstein (President and CEO of Novartis Oncology), stated that the data underscores Glivec as a durable, well-tolerated therapy where outcomes improve with long-term use. The filing includes a standard disclaimer regarding forward-looking statements, noting that actual results may differ due to:
- Unexpected clinical trial results or new clinical data.
- Regulatory actions, delays, or government regulation.
- Intellectual property protection challenges.
- Competition and pricing pressures.
Safety Profile: Glivec is generally well-tolerated. Common side effects include nausea, edema, muscle cramps, and skin rash. Serious adverse reactions include cardiac failure, thrombosis, and hepatic failure. Contraindications include known hypersensitivity to imatinib.
Investor Verification Checklist
- Verify the specific impact of the new EU and US approvals on future revenue projections for Glivec.
- Review the full Form 20-F for detailed financial statements, as this 6-K contains only 2005 historical financial data.
- Assess the competitive landscape for CML and other blood disorders given the expanded indications.
- Monitor regulatory developments regarding the safety profile, particularly cardiac risks and liver toxicity when combined with chemotherapy.
- Confirm the status of patent protection for Glivec in key markets to evaluate long-term exclusivity.